BONE MORPHOGENETIC PROTEIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the bone morphogenetic protein market with share of 39.2% in 2024, due to strong presence of major players and advanced healthcare infrastructure. With large pharmaceutical companies focusing on developing innovative bone graft substitutes, the region enjoys early access to new products.

Fastest-Growing Region: Asia Pacific

Asia Pacific region exhibits the fastest growth in the bone morphogenetic protein market due to increasing medical tourism, growing economy and massive patient population. Government initiatives to modernize healthcare systems and expand healthcare access across countries such as China and India are boosting adoption.

Bone Morphogenetic Protein Market Outlook for Key Countries

Robust Healthcare System Fueling Bone Morphogenetic Protein Market Expansion in the U.S.

The U.S. is experiencing significant growth in the bone morphogenetic protein market, driven by a robust healthcare system and the adoption of innovative technologies. In August 2020, the U.S. FDA approved recombinant bone morphogenetic proteins, morphogenetic protein-2, which has become a preferred treatment for bone-related surgeries in the U.S. According to the American Association of Neurological Surgeons (2021), 450,000 people in the U.S. are living with spinal cord injuries, and as per a January 2022 report, 80% of Americans experience back pain at some point.

Japan Market Growth is Driven by Aging Population

Japan bone morphogenetic protein market is significantly influenced by the country's aging population. According to the World Economic Forum in September 2023, over 28% of Japan's population is aged 65 or older. This demographic shift has led to an increase in orthopedic treatments, particularly joint replacements. According to National Library of Medicine, in 2023, Japan reported approximately 200,000 hip and knee replacements performed each year. Domestic companies like Olympus and Terumo are key players, focusing on delivering high-quality solutions tailored to the needs of older patients.

Growing Orthopedic Industry is Driven by Population and Healthcare Investments

China continues to lead globally with its vast population. The country has seen a rise in orthopedic procedures. For instance, according to the National Library of Medicine, in November 2020, over 1 million total joint surgeries were performed annually. Local manufacturers of bone morphogenetic protein proteins are gaining traction, contributing to an increasing acceptance of homegrown products alongside established international brands. The Chinese government's investment in healthcare infrastructure is also enhancing access to orthopedic treatments.

India's Growing Demand for Orthopedic Solutions and Bone Morphogenetic Protein Therapies

The India bone morphogenetic protein market is experiencing growth due to the rising demand for orthopedic solutions. The Indian Orthopaedic Research Group is focused on developing cost-effective BMP therapies to enhance access to advanced treatments for the population. According to the National Library of Medicine, in September 2020, India conducted approximately 400,000 joint replacement surgeries. This reflects a growing demand for orthopedic solutions as the population becomes more aware of treatment options for conditions like osteoarthritis.